These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9074692)

  • 1. Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for.
    Patrono C
    Cardiovasc Res; 1997 Feb; 33(2):295-6. PubMed ID: 9074692
    [No Abstract]   [Full Text] [Related]  

  • 2. Unstable coronary artery disease--need for long-term antithrombotic treatment. Aspirin alone is not sufficient, I would associate an anticoagulant.
    Wallentin L
    Cardiovasc Res; 1997 Feb; 33(2):292-4. PubMed ID: 9074691
    [No Abstract]   [Full Text] [Related]  

  • 3. Antithrombotic agents in coronary artery disease.
    Resnekov L; Chediak J; Hirsh J; Lewis HD
    Chest; 1989 Feb; 95(2 Suppl):52S-72S. PubMed ID: 2644104
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic agents in coronary artery disease.
    Cairns JA; Théroux P; Lewis HD; Ezekowitz M; Meade TW; Sutton GC
    Chest; 1998 Nov; 114(5 Suppl):611S-633S. PubMed ID: 9822067
    [No Abstract]   [Full Text] [Related]  

  • 6. Is optimal antithrombotic therapy after myocardial infarction well defined?
    McAnulty JH
    Curr Cardiol Rep; 2001 Jan; 3(1):53-5. PubMed ID: 11139799
    [No Abstract]   [Full Text] [Related]  

  • 7. [Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
    Shalaev SV
    Kardiologiia; 1989 Sep; 29(9):116-20. PubMed ID: 2687554
    [No Abstract]   [Full Text] [Related]  

  • 8. Contemporary view of the acute coronary syndromes.
    Moustapha A; Anderson HV
    J Invasive Cardiol; 2003 Feb; 15(2):71-9. PubMed ID: 12556619
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiplatelet agents prevent cardiac events in patients with coronary artery disease.
    Ishikawa K
    Intern Med; 1998 Feb; 37(2):199-202. PubMed ID: 9550609
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
    Arjomand H; Cohen M; Ezekowitz MD
    J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.
    Verheugt FW
    Haemostasis; 2000; 30 Suppl 2():122-7; discussion 106-7. PubMed ID: 11251355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic agents in coronary artery disease.
    Cairns JA; Lewis HD; Meade TW; Sutton GC; Théroux P
    Chest; 1995 Oct; 108(4 Suppl):380S-400S. PubMed ID: 7555191
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antithrombotic agents in acute myocardial infarction].
    Boschat J; Larlet JM; Gilard M
    Arch Mal Coeur Vaiss; 1998 Apr; 91 Spec No 2():19-26. PubMed ID: 9749272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives in the antiplatelet therapy of thrombotic disorders.
    Breddin HK
    Semin Thromb Hemost; 1989 Apr; 15(2):144-9. PubMed ID: 2665085
    [No Abstract]   [Full Text] [Related]  

  • 17. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy in the primary and secondary prevention of coronary-related death and infarction: focus on gender differences.
    Clyne CA
    Cardiology; 1990; 77 Suppl 2():99-109. PubMed ID: 2198101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in response to aspirin: do we understand the clinical relevance?
    Campbell CL; Steinhubl SR
    J Thromb Haemost; 2005 Apr; 3(4):665-9. PubMed ID: 15703034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.